The use of biomarker-based models in clinical settings to support early detection of and treatment for Alzheimer's disease.

Traditional detection of and treatment methods for Alzheimer’s disease (AD) undermine the critical period of preclinical AD, a pathogenic process that appears decades before clinical symptoms arise. In the preclinical stage, biomarkers stipulate the advent of pathogenic processes, providing a crucial framework to integrate early detection and intervention well before clinical symptoms become evident. I hypothesize that the presence of biomarkers is a crucial early indicator of changes in memory function in the preclinical stage of AD. To test this hypothesis, a systematic literature review will be applied to gauge biomarker detection in order to consider it as a potential predictive measure in treatment interventions.